MEDANTA Global Health Q2 FY26 results (Jul–Sep 2025) and concall
Global Health delivered a robust Q2 FY26 performance characterized by double-digit revenue and profit growth despite the initial drag from the newly launched Noida facility. The company is aggressively expanding its footprint, notably increasing its Mumbai project capacity by 50% and commencing construction in Guwahati. Management remains focused on high-complexity clinical work, which is driving ARPOB improvements across both mature and developing units.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
Q2 FY26: revenue up 39.2%, net profit up 34.6% against the same quarter last year.
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|
| Revenue | 665 | 812 | 803 | 882 | 926 +39% |
| EBITDA | 150 | 202 | 195 | 195 | 193 +29% |
| Net profit | 104 | 131 | 93 | 152 | 140 +35% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
